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INTRODUCTION AND OBJECTIVE OF THE 
INVESTIGATION
 Novel  drug  delivery  systems  are  being  employed  both 
experimentally and therapeutically to alter the distribution of drugs in the 
body with  an idea of  delivering them more efficiently and reducing the 
toxicity of the existing drugs. One such area in which research is gaining 
much  attention  is  “controlled  drug  delivery”  because  of  its  enhanced 
efficacy along with reduced toxicity.
It  have been reported that  40% of  the compounds developed in 
pharmaceutical industry are poorly soluble in water. A limiting factor to the 
in vivo performance of poorly water soluble drugs after oral administration 
is their inadequate ability to become wetter and getting dissolved in the 
gastrointestinal (GI) fluid.
Microspheres have more  advantages over  other  soluble  carrier’s 
liposomes. Liposomes have low drug entrapment efficiency, rapid leakage 
of water soluble drugs especially in the presence of blood components, 
poor stability  and method of preparation which are not  compatible  with 
large scale production requirements.  However  microspheres can entrap 
various molecules in a stable and reproducible way.
          
 Zidovudine is  a  nucleoside  reverse  transcriptase inhibitor  (NRTI) 
with  activity  against  Human  Immunodeficiency  Virus  Type  1  (HIV-1). 
Zidovudine  is  phosphorylated  to  active  metabolites  that  compete  for 
incorporation  into  viral  DNA.  They inhibit  the HIV reverse  transcriptase 
enzyme competitively and act as a chain terminator of DNA synthesis. The 
bioavailability of zidovudine can be increased by making the drug to get 
released  in  a  controlled  manner  by  incorporating  the  drug  in  certain 
biodegradable polymers.
The  aim  of  this  study  was  to  formulate  and  evaluate 
microencapsulated  controlled  release  preparations  of  Zidovudine  using 
ethyl  cellulose as the retardant material  with high entrapment efficiency 
and extended release. Ethylcellulose is a natural, biodegradable polymer 
and the method adopted for preparing microsphere was water-in-oil-in-oil 
(w/o/o) double emulsion solvent diffusion technique.
 The plan of work was designed as follows:-
 Preparation  of  zidovudine  microspheres  using  water-in-oil-in-oil  
(w/o/o) double emulsion solvent diffusion technique.
 Determination of size and shape of microspheres.
 Estimation of  percentage yield  of  the microspheres and is drug  
entrapment efficiency.
 Study of in vitro release from prepared microspheres.
INTRODUCTION
         Over the years we have learnt the optimization of drug therapy is of very 
great  importance  and  in  the  process  patience  convenience,  compliance, 
safety has to be taken into account.
         For many decades treatment of an acute disease or chronic illness has  
been  mostly  accomplished  by  deliver  of  drugs  to  patients  using  various 
pharmaceutical dosage forms like capsules, pills etc. These types of dosage 
forms require frequent dosing and thus causing inconvenience to patients.
       There are three types of drug delivery i.e. controlled delivery, targeted 
delivery  and  modulated  release.  Targeted  delivery  refers  to  the  systemic 
administration of drug carrier with the goal of delivering drug to specific cell  
types,  tissues and organs. Controlled release refers to the use of delivery 
device  with  the  objective  of  releasing  the  drug into  the  patient  body at  a 
predominant rate at a specific time or with specific release profiles. Modulated 
release implies release of the drug at variable rate which is controlled by 
various factors such as bio feedback, environmental conditions, sensor input 
or an external control device.
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Controlled  drug  delivery  is  the  one  which  delivers  the  drug  at  a 
specific rate locally or systemically for a specific period of time.
Controlled release dosage forms are being referred by a number of 
terminologies such as delayed action, extended action, prolonged release, 
slow release, gradual release, sustained release and timed release dosage 
forms.
Fig 1. Hypothetical plasma drug concentration-time profile
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OBJECTIVE OF CONTROLLED RELEASE
 Increase  in  patient  compliance  by  obtaining  extended  duration  of  
action
 Targeted drug action by using carriers or chemical derivatization to  
deliver drugs to a particular target cell type.
 Localized drug action by spatial or controlled release system adjacent 
to or in the diseased tissue or organ.
Advantages
1) Decrease in toxicity and adverse effects.
2) More consistent and prolonged therapeutic effect.
3) Improved patience compliance.
4) Reduced dosing frequency.
5) More uniform blood concentration.
6) A greater selectivity in pharmacological activity.
7) Avoidance of night time dosing.
8) Better drug utilization.
Disadvantages
1) Stability problems.
2) Toxicity due to dose dumping.
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3) Increased cost.
4) More rapid development of drug tolerance.
5) Increased variability among dosage units.
6) Poor in vitro and in vivo correlation.
7) Need for additional patient education and counseling.
8) Decreased systemic availability.
9) Retrieval  of  drug  is  difficult  in  case  of  toxicity  or  hypersensitivity  
reactions.
FACTORS GOVERNING THE DESIGN OF CONTROL RELEASE DOSAGE 
FORM:-
Drug related
• Aqueous solubility
• Partition coefficient
• Molecular size
• Drug stability
• Protein binding
Biological factors
• Absorption.
• Cardiac rhythm.
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• Distribution.
• Elimination.
• Duration of action.
• Margin of safety.
• Side effects.
• Diseased sates.
Physiological factors
• Prolonged drug absorption.
• Variability in GI emptying time.
• GI blood flow.
Pharmacological factors
• Sensitivity/tolerance.
• Changes in drug effect upon multiple dosing.
Pharmacokinetic factors
• Dose dumping.
• First pass metabolism.
• Enzyme induction/inhibition upon multiple dosing.
• Variability in urinary pH and its effect on drug elimination. (Jain., 1997)
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CLASSIFICATION OF ORAL CONTROLLED RELEASE SYSTEMS:
A) Continuous release systems
1) Dissolution controlled systems
a) Matrix type          
b) Reservoir type
2) Diffusion controlled release systems
           a) Matrix type               
b) Reservoir type
3) Dissolution and diffusion controlled release systems.
4) Ion exchange resin drug complexes.
5) Osmotic pressure controlled systems.
6) Slow dissolving salts and complexes.
7) pH dependant formulations
8) Hydrodynamic pressure controlled systems.
B) Delayed transit and continuous release systems.
1) Altered density systems
a) High density.
         b) Low density.
c) Floating.
2) Mucoadhesive systems.
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3) Size based systems.
C) Delayed release systems.
1) Intestinal release systems.
2) Colonic release systems.
Future developments in controlled drug delivery
The most exciting opportunities in controlled drug delivery lies in the 
area of responsive delivery systems, with which it will be possible to deliver 
drugs through implantable devices in response to a measured drug level or to 
deliver a drug precisely to a targeted site. Much of the developments of novel  
materials in controlled delivery are focusing on the preparation and use of the 
responsive polymers with specifically designed microscopic and macroscopic 
structural and chemical features.
Such systems include,
  Copolymers with desirable hydrophilic/hydrophobic interactions
  Complexation networks responding via hydrogen or ionic bonding
  Block or graft copolymers.
  Dendrimers or star polymers  as nanoparticles for immobilization of 
enzymes, drugs, peptides, or other biological agents.
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MICROENCAPSULATION
Microencapsulation is one of the most intriguing fields in the area of 
drug delivery systems. It is an interdisciplinary field that requires knowledge of 
the field of pure polymer science, familiarity with emulsion technology and an 
in-depth understanding of drug and protein stabilization. This method is also 
used to make controlled release dosage forms. Solids, liquids, gels can be 
entrapped  inside  one  or  more  polymeric  coatings.  The  structure  of 
microcapsules  depends on the  type  of  manufacturing  process and mostly 
spherical.  Pellets,  liposomes,  multiple  emulsions,  microcapsules  and 
microspheres  are  common  examples  of  microcapsulate  drug  delivery 
systems. (Edith mathiowitz., 2002)
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Table: 1 Classification of microencapsulation methods
PROCESS COATING MATERIAL SUSPENDED MEDIUM
Interfacial 
polymerization
Water soluble & 
insoluble monomers
Aqueous/organic solvent
Complex coacervation Water soluble 
polyelectrolyte
Water
Coacervation Hydrophobic polymers Organic solvent
Thermal denaturation Proteins Organic
Salting-out Water soluble polymer water
Solvent evaporation Hydrophilic or 
hydrophobic polymers
Organic solvent or water
Hot melt Hydrophilic or 
hydrophobic polymers
Aqueous/organic solvent
Solvent removal Hydrophilic or 
hydrophobic polymers
Organic solvents
Spray drying Hydrophilic or 
hydrophobic polymers
Air, Nitrogen
Phase separation Hydrophilic or 
hydrophobic polymers
Aqueous/organic 
solvent.
(i) Reasons for microencapsulation
 Sustained and controlled release
 Taste and odor masking
 Protection of drug against environment
 Delay of volatilization
 Enteric coating
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 Detoxification
 Conversion of oils and other liquids into solids for ease of handling
 Separation of flow of powders
 Isolation from tissues
 Safe handling of toxic substances
(ii) Properties of drugs used in microencapsulation
The core of microcapsules formulated may contain one or more drugs 
either a single drug or combination of drugs with suitable additives to form a 
liquid or solid phase. Liquid core may be composed of polar or non polar  
substantial  that  comprises the active ingredient  or that  acts as vehicle for 
dissolved  or  suspended  drugs.  The  solvent  properties  of  liquids  critically 
influence  the  rate  of  drug release  and  selection  of  coating  materials.  For 
drugs of low solubility with known bioavailability problems associated with low 
rates of  dissolution,  decrease in particle size of  suspended drugs may be 
important in enhancing  in vivo  absorption. Smaller microparticles also have 
faster release rates because of their increased surface area per unit volume 
or weight of core material. Solid cores are used more frequently than liquid 
cores. Very small core particles tend to give tend to give aggregation problem 
during production, because of the attraction force present at the surface of the 
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particles.  Larger  particles  can  cause  problems  because  of  their  rapid 
sedimentation rate. The shapes of these cores are also important. Density of 
cores is very important for controlling the transit time in GI tract. Increasing 
the density was the most important factor in prompting the retention of pellets 
in stomach. Decreasing density is important in floating type dosage forms. 
Swelling  of  the  core  with  disruption  of  coating  leads to  uncontrolled  drug 
release.
(iii)  Properties of polymers used for microencapsulation
The  selection  of  appropriate  coating  material  dictates  to  a  major 
degree the resultant physical and chemical properties of the microcapsules. 
The coating material should be capable of forming a film that is cohesive with  
the core material and the ideal coating material should be compatible and non 
reactive with the core material. The polymer coating should provide desired 
coating  properties  such  as  strength,  impermeability,  optical  properties, 
flexibility and stability. (Jain., 1997).
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MICROSPHERES AND MICROCAPSULES
Microspheres can be defined as spherical empty particles ranging in 
size  from  1  to  1000  micrometer.  Microspheres  are  characteristically  free 
flowing  powder  consisting  of  proteins  and  synthetic  polymers,  which  are 
biodegradable in nature.
            Microcapsules  consist of a well defined core and a well defined 
envelope;  the  core  can  be  solid,  liquid  or  gas,  the  envelope  is  made  of 
continuous process or non porous polymeric phase.
            It is also defined as a spherical particle with size varying from 50 nm 
to 2 mm containing a core substance.
           Microspheres have been investigated for intravenous and intra arterial 
targeting and delivery systems. Microspheres and Microcapsules have been 
injected in the vessels to ensure passive targeting of the drugs. The drug 
release is controlled by diffusion through the polymer matrix and/or by erosion 
of the polymer. The role of microspheres and microparticles depend on their 
size and site of injection.
         Microparticles of diameter smaller than 2µm can be injected in an 
intravenous, intra arterial and intra peritoneal manner in order to target the 
reticuloendothelial  system  (RES).  Intravenous  injection  of  Microspheres  of 
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size from 3-12 micrometer is intended to block the capillaries of the lungs, 
liver and spleen.(Vyas., 2002)
         Vessels can be hyperselectively embolized with drug loaded particulate  
materials of more than 10 micrometer. Microspheres of 100-300 micrometer 
size are the most appropriate embolic agents. They reach the intra lesional 
precapillary arteries and cause reduction of blood flow.       
Drug incorporation methods
1. The drug can be dissolved or homogeneously dispersed in the polymer
 (Matrix device-microsphere type).
2. Drugs can be dissolved or homogenously dispersed in the polymer 
(Matrix device- Microsphere type).
15
Fig: 2 various configurations of a)microcapsules and b)microspheres 
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 (i) Advantages of microspheres
1. Taste and odor masking.
2. Protection of the drugs against the environment (moisture, light, heat, 
and/or oxidation) and vice versa (prevention of pain on injection).
3. Delay of volatilization.
4. Conversion of oils and other liquids to solids for ease of handling.
5. Separation  of  incompatible  materials  (other  drugs  or  excipients
such as buffers)
6. Safe handling of toxic substances.
7. Improvement of flow of powders.
8. Aid in dispersion of water-insoluble substances in aqueous media.
9. Production of sustained release, controlled release and targeted 
medications.
 (ii) Route of administration
           Route of administration is selected depending on the drug properties, 
disease states being treated and the age condition of the patient. Desirable 
properties of microspheres to be used for delivery will also change depending 
on route of administration.
18
a) Oral delivery
Oral delivery is the simplest route of drug administration. Constraints of 
the  oral  route  are  numerous on  the  whole  it  offers  potential  danger  than 
parental route. The relatively brief transit time of about 12 hours through the 
GI tract limits the duration of action that can be expected via the oral route. 
Recently, it has been reported that microspheres of less than 10µm in size 
are taken up by peyer’s patches and may increase the retention time in the 
stomach. Also microspheres made of polymers with mucoadhesive properties 
get attached to stomach or intestine and prolong the residence time in the 
stomach.  Bioavailability  of  drugs  with  limited  solubility  in  the  stomach  or 
intestine and small absorption rate constant can be increased by increasing 
the retention time in the stomach. Improved drug delivery was observed in 
mucoadhesive  propertied  microspheres  when  compared  to  non 
mucoadhesive propertied microspheres administered alone.(Jain., 1997)
b) Parenteral delivery
Most  of  the microsphere  based  controlled  delivery  systems  are 
developed  with  the  aim of  using  them for  parenteral  administration.  Drug 
released  is  completely  absorbed  in  this  case.  Microspheres  used  for 
parenteral delivery should be sterile and should be dispersible and compatible 
in a suitable vehicle for injection. Surfactants in small concentration are often 
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necessary  for  reconstituting  hydrophobic  particles  for  injection  in  aqueous 
vehicles, which are reported for certain adverse tissue reactions and affect 
the release of incorporated drug.
PROCESS 
Polymers used
Synthetic polymers
Non-biodegradable
 PMMA
 Acrolein
 Glycidyl methaacrylate
 Epoxy polymers
Biodegradable
 Lactides and glycolides
 Polyalkyl cyano acrylates
 Polyanhydrides
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NATURAL MATERIALS
Proteins
 Albumin
 Gelatin
 Collagen
Carbohydrates
 Starch
 Agarose
 Chitosan
Chemically modified carbohydrates
 DEAE cellulose
 Poly (acryl dextran)
 Poly(acryl starch)
Prerequisites for ideal microparticulate carriers
 Longer duration of action
 Control of content release
 Increase of therapeutic efficacy
 Protection of drug
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 Reduction of toxicity
 Biocompatibility
 Sterilizability 
 Relative stability
 Dispersability or water solubility
 Bioresorbability 
 Targetability 
 Polyvalent
(iv) Preparation of microspheres
 The preparation of microspheres should satisfy certain criteria,
 The ability to incorporate reasonably high concentrations of drug.
 Stability of the penetration after synthesis  with  clinically acceptable  
shelf life.
 Controllable particle size and dispersability in aqueous vehicles for  
injection.
 Release of active ingredient with good control over a wide time scale.
 Biocompatibility with a controllable biodegradability.
 Susceptibility to chemical modification.
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(v) Methods of preparation
The method of preparation and its choice are equivocally determined 
by some formulation and technology related factors as mentioned below,
 The particle size requirement.
 The drug or protein should not be adversely affected by the process.
 Reproducibility of the release profile and the method.
 No stability problem.
 There should be no toxic products associated with the final product.
1.  Solvent evaporation
This technique is based on the evaporation of the initial phase of an 
emulsion  by  agitation.  Initially  the  polymeric  supporting  material  was 
dissolved in a volatile organic solvent. The active ingredient that has to be 
encapsulated is then dispersed of and dissolved in organic solution to form 
suspension, emulsion or solution. In the following step the organic phase is 
emulsified under agitation in a dispersing phase consisting of the non solvent 
of the polymer, which is immiscible with the organic solvent, which contains 
an appropriate tension active additive. Once emulsion is stabilized, agitation 
is  maintained  and  solvent  is  the  creation  of  solid  microspheres.  On  the 
completion  of  solvent  evaporation  process,  the  microspheres  held  in 
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suspension in the continuous phase recovered by filtration of centrifugation 
and are washed and dried.
2. Thermal and cross linking
          Microspheres made from natural polymers are prepared by a cross 
linking process; the polymers include gelatin,  albumin, starch and dextran. 
Water in oil emulsion is prepared, where the water phase is a solution of the 
polymer,  which  contains  the  drug  to  be  incorporated.  The  oil  phase  is  a 
suitable vegetable oil or oil-organic solvent mixture containing an oil- soluble 
emulsifier. Once the desired water-oil emulsion is formed, the water soluble 
polymer is solidified by some kind of cross linking process. This requires a 
thermal  treatment  or  the  addition  of  chemical  cross  linking  agent  like 
glutaraldehyde. In the chemical and thermal cross linking process both the 
amount of chemical and intensity of heat applied are critical in determining the 
swelling properties and release profiles of microspheres. If glutaraldehyde is 
used as cross linking agent, residual amounts can have toxic effects.
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3. Precipitation
A variation on the evaporation method is the precipitation method. The 
emulsion consists of polar droplets dispersed in a non polar medium. Solvent 
may be removed from the droplets by the use of a co solvent. The resulting 
increase in the polymer-drug concentration causes a precipitation forming a 
suspension.
4. Freeze drying
The  technique  involves  the  freezing  of  the  emulsion;  the  relative 
freezing  points  of  the  continuous-phase  solvent  is  usually  organic  and  is 
removed  by  sublimation  at  low  temperature  and  pressure.  Finally,  the 
dispersed phase solvent of the droplets is removed by sublimation, leaving 
polymer-drug particles.
3. Spray drying and spray congealing
Spray drying and spray congealing methods are based on the drying of 
the  mist  of  polymer  and  drug  in  air.  Depending upon  the  removal  of  the 
solvent or the cooling of the solution, the two processes are named spray 
drying and spray congealing respectively. The polymer is first dissolved in an 
organic volatile solvent such as dichloromethane, acetone etc. the drug in the 
solid  form  is  then  dispersed  in  the  polymer  solution  under  high-speed 
homogenization. This dispersion is then atomized in a stream of hot air. The 
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atomization leads to formation of small droplets or the fine mist form which 
the  solvent  evaporates  instantaneously  leading  to  the  formation  of 
microspheres in a size range of 1-100µm. Microspheres are separated from 
the hot air by means of the cyclone separator while the traces of solvent are  
removed by vacuum drying.(Jain., 1997).
      Very  rapid  solvent  evaporation,  however  leads  to  the  formation  of  
microparticles.
Advantages
→ Feasibility of the operation under aseptic conditions.
→ The process is rapid.
→ Suitable for both batch and bulk manufacturing.
→ This technique can be use to encapsulate large number of drugs.
4. Phase separation and coacervation techniques
Phase  separation  method  is  specially  designed  for  preparing  the 
reservoir  type  of  the  system,  i.e.  to  encapsulate  water  soluble  drugs e.g. 
peptides,  proteins,  however  some  of  the  preparations  are  of  matrix  type 
particularly, when the drug is hydrophilic in nature e.g. steroids. In matrix type 
device, the drug or the protein is soluble in polymer phase. The process is 
based  on  the  principle  of  decreasing  the  solubility  of  the  polymer  in  the 
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organic  phase  to  affect  the  formation  of  the  polymer  rich  phase  called 
coacervates. The coacervation can be brought about by addition of the third 
component to the system which results in the formation of two phases, one is 
rich in polymer and the other, i.e. supernatant, depleted of the polymer. This 
is achieved by the addition of the salt, non-solvent addition, addition of the 
incompatible polymer or change in pH.
           In this technique, the polymer is first dissolved in a suitable solvent and 
then the drug is dissolved by making its aqueous solution. Phase separation 
is then accomplished by changing the solution conditions by using any of the 
method above. The process is carried out under continuous stirring to control 
the size of microparticles.
(V) Loading of drug
The active components are loaded over the microspheres principally 
using two methods,  i.e.  during preparation of the microsphere or after the 
formation of microspheres by incubating them with drug or protein. The active 
component can be loaded by means of the physical  entrapment,  chemical 
linkage and surface absorption.
            Maximum absorption can be achieved by incorporating the drug  
during  the  time  of  preparation  but  it  may  get  affected  by  many  other 
processes such as method of preparation, presence of additives (e.g. cross 
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linking  agent,  surfactants,  stabilizers  etc),  the  loading  is  carried  out  in 
preformed microspheres by incubating them with a very high concentration of 
drug  in  a  suitable  solvent.  The  drug  gets  loaded  in  these  microspheres 
through diffusion or penetration through the pores in the microspheres as well 
as adsorption in their surface. The solvent is then removed leaving the drug 
loaded microsphere.
           The Freundlich model is applied to determine the adsorption of the 
drugs. The Freundlich equation is,
                                    X/M = KCpeq
    Where,
    K= Constant related to the capacity of adsorbent for the adsorbate.
    P=   Constant related to the affinity of the adsorbent for the adsorbate.
(vi) Release of drug from microspheres
            The rate of drug release from the microspheres dictates their 
therapeutic action. Drug release is governed by the molecular structure of the 
drug and the resistance of polymer to degradation and the surface area and 
porosity of microspheres.
            Reservoir delivery systems extend the residence time of drug within 
the systemic circulation originally focused on zero-order dissolution kinetics.
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           In porous polymeric systems the rate of drug release is dictated by the  
device surface area, which is linked directly to its shape. The rate of release 
from microspheres may be result of polymer erosion or diffusion.
           The internal structure may vary as a function of microencapsulation 
process employed. Reservoir microcapsules have a core of drug coated with 
polymer.  The  drug  is  distributed  homogenously  throughout  the  polymeric 
matrix in monolithic microspheres.
          The mechanism of drug release at a controlled rate from microspheres 
include diffusion of  drug through a polymeric excipients, diffusion of trapped 
drug as polymer erodes, and release of drug through pores in the polymeric 
excipients. Increasing the surface area, by reducing the particle size, results 
in an increased release rate. The path length travelled by the drug in the 
matrix  can  be  controlled  by  manipulating  the  microsphere  loading. 
Microspheres  with  high  drug  content  release  the  outline  ingredient  more 
rapidly than those with a low load. Thicknesses of the polymer also influence 
release rate.
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Mechanism of drug release
         Factors affecting the release of drug from the particulate system in 
relation with drug, microspheres and bio environment.    
 Drug
 Position in microspheres.
 Molecular weight.
 Concentration.
 Interaction with matrix.
Microspheres
Type and amount of matrix polymer.
 Size and density of microspheres.
 Extent of cross linking, denaturation or polymerization.
 Adjuvants.
Environment
 pH.
 Polarity.
 Presence of enzyme.
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The geometry of carrier, i.e., whether it is reservoir type where the drug 
is present as a core, or matrix type in which drug is dispersed throughout the 
carrier, governs overall  release profile of drug or active ingredients.  (Jain.,  
1997).
SYSTEMS
Reservoir type system
Release from the reservoir type system with rate controlling membrane 
proceeds by  first  penetration  of  water  through the  membrane followed  by 
dissolution of the drug in the penetrating dissolution fluid. The dissolved drug 
after partitioning through the membrane diffuses across the stagnant diffusion 
layer. The release is essentially governed by the Fick’s first law of diffusion 
as,                          J= −D dcdx
Where,
                      J = flux per unit area.
                      D = diffusion coefficient.
           Diffusion across the membrane determines the effectiveness of the  
carrier  system.  The  release  rate  from  the  carriers  can  be  modified  by 
changing both the composition and thickness of the polymeric membrane.
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Matrix type system
Release  profile  of  the  drug  from  this  type  of  the  device  critically 
depends  on the  state  of  drug  whether  it  is  dissolved  or  dispersed  in  the 
polymer matrix.
           In case of the drug dissolved in the polymeric matrix, amount of drug, 
and the nature of polymer affect the release profile. If  this is the case the 
amount of drug appearing in the receptor phase at “t” is approximated by two 
separate equations. The first equation determines the 60% of drug release 
profile at the later stage.
           dMtdt
=2 Mx D /π∫2 t 1 /2
dMt
dt
=  8 DM x / ∫ 2 exppi2 Dt+/∫ 2
Where, 
l = thickness of polymer slab.
D = diffusion coefficient.
Mx = total amount of drug present in the matrix.
Mt = amount of drug released in time “t”.
When the drug is dispersed throughout the polymer matrix then the 
release profile follows higuchi’s equation.
                           
dM t
dt
 =  A2 (2DCsCo)
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  Where,
          A = area of matrix.
          Cs = solubility of the drug in matrix.
          Co = total concentration in the matrix.
(iv) Fate of microsphere in the body
The  knowledge  about  the  fate  of  microspheres  after  parenteral 
administration is very important  for  designing a drug delivery system. The 
biological  fate  of  administered  microspheres  has  been  studied  by 
radiolabelling  techniques.  14C,  131I,  125I,  and  99Tc  are  being  used  for 
radiolabelling. Fluoroscein labeling has also been found useful for studying 
the fate of microspheres in vivo.
Table: 2 proposed mechanism for uptake of microspheres
SITE SIZE RANGE FATE
Enterocyte/Endocyte <220 nm RES uptake
Paracellular uptake 100-200 nm Unknown
Intestinal macrophage 1 µm MLN
Persorption 5-150 µm Blood and Excretory fluids
Peyer’s Patches 20 nm - 10 µm PP and MLN
Follicle associated 
epithelium < 750 nm MLN
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(v) Applications of microspheres.
 Microspheres in vaccine delivery
 Antigen release
 Immune system
 Targeting using particulate carriers (ocular, intranasal, oral)
 Magnetic microspheres, Imaging
 Monoclonal antibodies.
 Microsponges: topical porous microspheres.(Jain., 1997).
ETHYL CELLULOSE MICROSPHERES
               Ethyl cellulose microspheres were prepared based on the principle 
of double emulsion solvent diffusion technique with certain modifications. The 
rational  for  selecting EC for  the shell  material  was  that,  this  substance is 
commonly  used  as  an  additive  in  foods  and  drug  because  of  its  high 
inertness, and forms a stable, semi-permeable capsular membrane.
              Ethyl cellulose is synthetic polymer; synthetic polymers have the 
advantage that they can be easily and reproducibly prepared. This can be 
copolymerized  with  one  another  to  alter  the  physical,  chemical  and 
mechanical properties and can be prepared as low or high molecular weight 
material  by  suitable  reaction  conditions.  Chemical  bonds  which  are 
susceptible  to  degradation  include  amides,  esters,  orthoesters,  acetyls, 
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glycosides and related groups. biodegradability of the polymer depends on 
many factors such as polymer structure, molecular weight ,physical form of 
the  polymer  and environment  in  which  the  polymer  is  placed since many 
proteolytic enzymes specifically catalyzes the hydrolyses of peptide linkages 
adjacent  to  substituted  proteins,  substituted  polymers  containing  benzyl, 
hydroxyl ,carboxyl-methyl and phenyl groups have been prepared to improve 
biodegradability.
DOUBLE EMULSION SOLVENT DIFFUSION TECHNIQUE:
                The technique was based on formation of an emulsion by agitation. 
Initially the drug and the polymeric material are dissolved in the solvent. Then 
the  primary  emulsion  was  formed  by  adding  water  little  by  little  into  the 
solvent,  drug and polymer mixture which stirring was done simultaneously 
using a mechanical stirrer.  After the emulsion was formed the stirring was 
stopped. Then the oily phase was taken along with surfactant and the primary 
emulsion  formed  was  added  to  the  oil  phase  slowly  while  stirring  was 
continued at a constant speed. The process was continued for two hours and 
then  a  stabilizing  agent  was  added  in  order  to  harden  the  preformed 
microspheres and stirring was further continued for one more hour.
Then the product formed was washed with an suitable compound and 
then filtered in order to remove the oily phase and air dried.
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REVIEW OF LITERATURE 
Chowdary  et  al.,  (1989)  prepared on  microcapsules  using  calcium 
alginate and reported that method based on emulsification of a solution of 
sodium alginate containing the drug in an immiscible liquid medium followed 
by  curing  with  calcium  chloride  to  result  in  spherical  calcium  alginate 
microcapsules  was  reported.  Aspirin,  diazepam  and  nitrofurantoin  were 
encapsulated by this method.  The microcapsules were found to be slow and 
spread over extended period of time.  The release mechanism was found to 
be of diffusion type.
Khawla  abu-izza  et  al., (1996) prepared  zidovudine-loaded  (AZT-
loaded)  sustained  release  microspheres  and  optimized  using  response 
surface methodology. Entrapment efficiency, yield, and percentage of loose 
surface crystals  were  investigated.  All  the  investigated response variables 
were found to be highly dependent on the formulation variables, with strong 
interactions observed between the formulation variables. It  was found that 
optimum overall  desirability  of  AZT  microspheres  can  be  obtained  at  low 
levels of SDS and ethyl acetate concentrations and at intermediate levels of 
drug to polymer ratio. An optimized formulation was prepared under these 
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experimental conditions and evaluated for individual responses and overall 
desirability. It is clear that the loading efficiency was 
highly dependent on the D: P ratio. As the theoretical loading increased, the 
loading efficiency increased significantly. A fixed amount of AZT is probably 
lost to the aqueous phase during the formation of microspheres and this loss 
obviously  has  a  more  detrimental  effect  on  the  loading  efficiency  of 
microspheres with relatively lower drug content.
Perumal., (2001) proposed a method to prepare modified release of 
ibuprofen  by  emulsion  solvent  diffusion  technique.  The  technique  was 
optimized for following process variables: the absence or presence of baffles 
in the reaction vessel, agitation rate and drying time. Thereafter, the influence 
of various formulation factors on the microencapsulation efficiency, in vitro 
drug  release  and  micrometric  properties  were  examined.  The  variables 
included  the  methaacrylic  polymer,  Eudragit  RS  100,  ibuprofen  and  the 
volume of ethanol used during microencapsulation. The results obtained were 
then  interpreted  on  a  triangular  phase  diagram  to  map  the  region  of 
microencapsulation,  as  well  as  those  formulations  that  yielded  suitable 
modified release ibuprofen microspheres.
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Gonzalez-Rodriguez  et  al., (2002)  prepared  Alginate  /chitosan 
particulate systems for diclofenac sodium release by ionic gelation (Ca2+ and 
Al3+)  and  characterized  by  scanning  electron  microscopy  and  differential 
scanning  calorimetry.  The release of  diclofenac  sodium was  prevented  at 
acidic pH, while it was complete in a few minutes when pH is raised up to 6.4 
and 7.2.The alginate / chitosan ratio and nature of gelifying cation allow a 
control of the release rate of the drug.
Bhupender Singh  et al., (2002) Designed, developed and optimized 
controlled  release  microcapsules  of  diltiazem  hydrochloride  reported  that, 
microcapsules were formulated as per factorial design taking rate controlling 
coat polymer and emulgent that is ethylcellulose and span 80 respectively.  
The release of drug follows fickian drug release. The release was found to be 
quite  regulated for  controlled release purpose (t80%  ≈ 9.5hr)  with  little  dose 
dumping (release up to 16hr≈ 99%).
Sajeev  et  al.,  (2002) formulated  and  evaluated  microencapsulated 
preparations of diclofenac sodium (DFS) using different proportions of ethyl  
cellulose (EC) as the retardant material to extend the release. The formulated 
microcapsules were then compressed into tablets to obtain controlled release 
oral  formulation.  Phase  separation  coacervation  technique  was  used  to 
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prepare  microcapsules  of  DFS  using  different  proportions  of  EC  in 
cyclohexane Physical  characteristics of  microcapsules and their  tablets,  in 
vitro release pattern of the designed microcapsules and their tablets prepared 
from them were studied using USP dissolution apparatus (USP 2000) type II  
(paddle method) in triple distilled water.  The prepared microcapsules were 
white free and owing and spherical in shape. All tablets were good of quality 
with  respect  to  appearance,  drug  content  uniformity,  hardness,  weight 
variation, friability, and thickness uniformity a good correlation was obtained 
between drug release (t60) and proportion of in the microcapsules. In the case 
of  tabletted  microcapsules,  very  good  correlation  could  be  established 
between release rate constant (k) and proportion of EC. All the formulations 
were highly stable and possessed reproducible release kinetics across the 
batches.
Mishara et al., (2003) prepared chitosan – alginate microcapsules for 
colon  specific  delivery  of  metronidazole  and  reported  that  microcapsules 
prepared  by  calcium  chloride  cross  –  linking  method  with  different 
concentration of sodium alginate and chitosan. Then they were treated for 
three different coating with reduced molecular weight chitosan, guar gum and 
enteric  coatings  with  cellulose  acetate  pthalate.  Chitosan  concentration 
significantly affected the strength and flexibility of membrane. Drug loading 
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was decreased with increase in the weight of either encapsulating polymer or 
chitosan  and  different  coatings.  In  vitro drug  release  was  found  to  be 
decreased  with  increasing  chitosan  and  sodium  alginate  concentrations. 
Among the three coatings reduced molecular weight chitosan coating gave 
much lower drug release and exhibit colon specificity.
Sharbaraya  et al.,  (2003) prepared chitosan microspheres of 
metaprolol  tartarate  by  phase  separation  emulsification  technique  and 
microspheres are investigated for sustained release. Percentage yield  was 
found to be 80-86 percent. The size range of microspheres varied from 3.5-
31.5 µm. the  in vitro  release studies were carried out at different pH for a 
period of 10 hours and was compared with that of pure drug.
Dandagi  et  al., (2004) prepared  microcapsules  of  verapamil 
hydrochloride by Ionotropic gelation technique and reported that, increase in 
speed of rotation of calcium chloride (counter-ion) solution, leads to decrease 
in pellet size. Also it was found that with the increase in harvesting time, the 
pellet formed in turn decreased the drug entrapment efficiency. The release of 
the drug from micro pellets was found to be following non-Fickian diffusion 
mechanism,  which  accounts  for  the  prolonged  release  of  Verapamil 
Hydrochloride.
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Chowdary  et  al., (2004) prepared  ethyl  cellulose  microspheres  of 
glipizide by industrially feasible emulsion-solvent evaporation technique and 
the microspheres were investigated. The microspheres were discrete and free 
flowing. Encapsulation efficiency was in the range of 81-91 percent. Glipizide 
release from microspheres was slow, diffusion controlled and extended over a 
period of 10 d depending on the core: coat ratio, wall thickness and size of 
microspheres.  In  the  in  vivo,  the  microspheres  produced  a  sustained 
hypoglycemic effect 6 d in normal rabbits. These microspheres were found to 
be suitable for parenteral controlled release.
Cui-Yun Yu  et al.,  (2005) prepared alginate based microparticles  for 
the sustained release of antineoplastic drugs. The drug loaded microparticles 
were fabricated using a very convenient method under very mild conditions, 
i.e.,  directly  shredding  the  drug  loaded  beads  into  microparticles  in  a 
commercial food processor. The mean sizes of the obtained microparticles 
were  between  100  and  200µm.  To  effectively  sustain  the  drug  release, 
alginate microparticles were reinforced by chitosan during gelation. The drug 
release  from the  chitosan-reinforced  alginate  microparticles  was  obviously 
slower  than  that  from  the  unreinforced  microparticles.  The  effect  of  the 
reinforcement conditions on the drug release property of the microparticles 
was  studied,  and  the  optimized  concentration  of  chitosan  solution  for 
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reinforcement was identified. The effects of drug feeding concentration and 
pH value of the release medium on the drug release were investigated. The 
in vitro release shows that chitosan reinforcement could effectively sustain the 
release  of  the  drugs  with  low  molecular  weights.  And  the  efficiency  of 
reinforcement is affected by the concentration of chitosan solution.
Martinac  et  al.,  (2005)  prepared loratidine-loaded  microspheres  by 
spray drying of dispersions, emulsions and suspensions differing in polymeric 
composition  and  solvents  used.  Composed  microspheres  were 
obtained  by  spray  drying  of  two  phase  systems  of  Chitosan  and  ethyl 
cellulose (EC). Microspheres differed in EC/CM weight ratio (0:1, 1:2 and 1:3) 
and in loratidine/polymers weight ratio (1:6 and 1:8). Tensile studies showed 
that both, EC/CM ratio, and the type of spray dried system influenced the 
bioadhesive  properties  of  microspheres  in  a  way  that  microspheres  with 
higher Chitosan content were more bioadhesive and microspheres prepared 
from  suspensions  were  more  bioadhesive  than  those  prepared  from 
emulsions, regardless of same polymeric combination.
Gohel et al., (2005) Prepared and optimized sugar crosslinked gelatin 
microspheres  of  Diclofenac  sodium  reported  that  sugar  (e.g.  glucose, 
fructose) can induce cross linking of gelation for the preparation of modified 
release microspheres. The microspheres which were prepared by emulsion 
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crosslinking method revealed that, the parameters such as drug to gelation 
ratio, volume of light liquid paraffin and stirring rate were found to affect the 
morphology and drug release of microspheres.
Sunit Kumar Sahoo et al., (2005) prepared Eudragit microspheres of 
stavudine by solvent evaporation technique. The prepared microspheres were 
characterized for their micromeritic properties and drug loading, as well  by 
Fourier  transform  infrared  spectroscopy  (FTIR),  differential  scanning 
calorimetry,  x-ray powder diffractometry and scanning electron microscopy. 
The drug-loaded microspheres showed 67-91% of entrapment and release 
was extended up to 6 to 8 h. The infrared spectra and differential scanning 
calorimetry thermographs showed stable character of stavudine in the drug-
loaded microspheres and revealed the absence of drug-polymer interactions. 
The best-fit release kinetics was achieved with Higuchi plot followed by zero 
order and First order. The release of stavudine was influenced by the drug to  
polymer ratio and particle size & was found to be diffusion controlled.
Malay  Kumar  Das  et  al., (2006) prepared  zidovudine-loaded 
ethylcellulose  microspheres  by  w/o/o  double  emulsion  solvent  diffusion 
method with high entrapment capacity and sustained release is described. 
The prepared microspheres were characterized by entrapment efficiency,  in 
vitro  release behavior, differential scanning calorimetry (DSC) and scanning 
electron microscopy (SEM). The drug-loaded microspheres showed 32 and 
43
55% entrapment capacity. The DSC thermograms confirmed the absence of 
any drug-polymer  interaction.  SEM studies  showed  that  the  microspheres 
were  spherical  and  porous  in  nature.  The  in  vitro  release  profiles  from 
microspheres  of  different  polymer-drug  ratios  were  best  fitted  to  Higuchi 
model  with  high  correlation  coefficient  and  the  n  value  obtained  from 
Korsmeyer-Peppas  model  was  ranged  between  0.23  and  0.54.  The  drug 
release was found to be diffusion controlled mechanism.
Sameer Sharma  et al.,  (2006)  prepared low density multiparticulate 
system for pulsatile release of meloxicam and reported that floating pulsatile 
drug delivery system was developed using porous calcium silicate (Florite 
RE)  and  sodium  alginate,  for  time  and  site  specific  drug  release  of 
meloxicam. Drug adsorbed Florite RE powder was used to prepare calcium 
alginate beads by ionotropic gelation method, using 3  factorial designs and 
evaluated.  The  floating  time  was  controlled  by  density  of  beads  and 
hydrophobic  character  of  drug.  A  pulsatile  release  of  meloxicam  was 
demonstrated  by  a  simple  drug delivery  system which  could  be useful  in 
chronopharmacotherapy of rheumatoid arthritis.
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Das  et  al.,  (2006) prepared  Zidovudine-ethylcellulose  microspheres 
were prepared by water-in-oil-in-oil double emulsion solvent diffusion method. 
Spherical free flowing microspheres having an entrapment efficiency of 32-
54% were obtained. The effect of polymer-drug ratio, surfactant concentration 
for  secondary  emulsification  process,  volume  of  processing  medium  and 
stirring speed of secondary emulsification process was evaluated with respect 
to  entrapment  efficiency  and  in  vitro drug  release  behaviors.  The  in  vitro 
release  profiles  from  microspheres  of  different  polymer-drug  ratios  were 
applied on various kinetic models. The higher drug loading typically results in 
lower encapsulation efficiency due to higher concentration gradients resulting 
the  drug  to  diffuse  out  of  the  polymer/solvent  droplets  to  the  external 
processing  medium.  The  viscosity  of  the  polymer  solution  at  higher  drug 
loading  was  very  high  and  was  responsible  for  the  formation  of  larger 
polymer/solvent droplets. It caused a decrease rate of entrapment of drug due 
to slower hardening of the larger particles, allowing time for drug diffusion out 
of  the  particles,  which  tends  to  decrease  encapsulation  efficiency.  The 
attempt  to  prepare  controlled  release  microspheres  of  zidovudine  with 
increased entrapment efficiency was successful, even though the entrapment 
efficiency was still  lower compared to the same process reported for other 
hydrophilic drugs.
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Amitava  Ghosh  et  al., (2007)  prepared  lamivudine  incorporated 
microspheres composed of ethyl  cellulose as release controlling polymeric 
material.  Microspheres  were  prepared  from  various  methods,  namely, 
modified  w/o/o  emulsion  solvent  evaporation  method,  o/w/o  type  emulsion 
solvent  evaporation  method,  thermal  change  technique,  Nobel  Quasi 
emulsion  solvent  diffusion  method,  meltable  dispersion  method,  phase 
separation  coacervation  method  (non-solvent  addition  technique).  The 
prepared microspheres were evaluated for parameters such as, percentage 
yield,  drug entrapment efficiency,  particle size determination, drug polymer 
interaction, stability studies, and in vitro drug release kinetic study. The drug 
polymer  ratio  and  drug  load  kept  constant  throughout  the  current 
investigation.  Among  the  methods  adopted  in  this  study,  thermal  change 
method was most  successful  in  sustaining the release of  lamivudine from 
ethyl cellulose microspheres.
Li Jun et al., (2007) prepared procaine haemoglobin microcapsules of 
chitosan  –sodium  alginate. Microcapsules  were  prepared  by  using  an 
emulsification –gelation method. Microcapsules possess a relatively narrow 
and normal Gaussian distribution. The procaine hemoglobin released from 
microcapsules  were  extended for  more  than  one  month.  Chitosan-sodium 
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alginate –hemoglobin microcapsules  were expected to become an artificial 
oxygen carrying therapeutic agent with SR for intravenous injection.
Tamizharasi  et al., (2007)  Formulated, characterized and carried out 
In-vitro release  kinetics  of  Aceclofenac  loaded  poly  (ε -caprolactone) 
microspheres and reported that,  drug to  carrier  ratio-(1:4)  showed highest 
drug  entrapment  and  the  drug  released  up  to  15  hour  and  found  to  be 
sustained. There was no interaction between drug and polymer.
Prakash et al., (2007) prepared and evaluated microcapsules for the 
controlled  release  of  lamivudine  using  various  cellulose  polymers.  The 
microcapsules  were  prepared  by  the  solvent  evaporation  method.  The 
prepared  microcapsules  were  characterized  for  the  percent  drug  content, 
entrapment efficiency, FTIR, DSC, scanning electron microscopy (SEM) and 
in  vitro  dissolution  studies.  The  entrapment  efficiency  was  76-86%.  The 
release of drug from the microcapsules extended up to 8 to 12 hours. FTIR 
and  DSC thermograms  showed  the  stable  character  of  lamivudine  in  the 
microcapsules. SEM revealed that the microcapsules were porous in nature. 
The  release  kinetics  data  and  characterization  studies  proved  that  drug 
release  from  microcapsules  was  diffusion  –  controlled  and  that  the 
microcapsules were stable.
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Dong Xun Li et al., (2007) prepared ibuprofen microcapsule by spray 
drying technique. To develop a novel ibuprofen-loaded gelatin microcapsule 
with bioavailability enhancement, the effect of spray-drying conditions, gelatin, 
ibuprofen and sodium lauryl sulfate on the ibuprofen solubility and the amount 
of  ethanol  encapsulated  in  gelatin  microcapsule  were  investigated.  The 
ibuprofen solubility and amount of  encapsulated ethanol increased as inlet 
temperature  and  amount  of  sodium  lauryl  sulfate  increased,  reached 
maximum at 105oC and 0.6%, respectively and after that  followed a rapid 
decrease.  This  ibuprofen  loaded  gelatin  microcapsule  gave  significantly 
higher  initial  plasma  concentrations,  Cmax and  AUC of  ibuprofen  than  did 
ibuprofen powder, indicating that the drug from gelatin microcapsule could be 
more orally absorbed in rats. Thus, the ibuprofen-loaded gelatin microcapsule 
developed using spray drying technique with gelatin was a more effective oral 
dosage form for poorly water-soluble ibuprofen.
Parul Trivedi et al., (2008) prepared and characterized of aceclofenac 
microspheres. The microspheres were prepared by o/w emulsion – solvent 
evaporation technique using Eudragit S 100, RL 100 and RS 100] to provide 
controlled  release  and  minimizes  local  side  effects  by  avoiding  the  drug 
release  in  the  upper  gastro  intestinal  track.  Prepared  microspheres  were 
subjected to micromeritic evaluation, drug loading studies, and  in-vitro drug 
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release  studies.  The  drug  polymer  concentration  in  the  dispersed  phase 
influence the particle size and drug release properties. All the formulations at  
higher pH follow the Matrix-Higuchi model.
Das et al., (2008) prepared Furosemide loaded alginate microspheres 
by  ionic  cross  linking  technique.  Morphology  and  release  characteristics 
reported  that,  entrapment  efficiency  and  particle  size  increased  with  the 
increased sodium alginate concentration. The kinetic modeling of the release 
data indicate that furosemide release from the alginate microspheres follow 
anomalous transport  mechanism after  an  initial  lag  period  when  the  drug 
release mechanism was found to be Fickian diffusion controlled.
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DRUG AND POLYMER PROFILE
DRUG PROFILE
ZIDOVUDINE  
                               
Empirical formula :  C10H13N5O4  
Relative molecular mass : 267.2
Melting point :  106-112oC
Chemical name : 1-[(2R, 4S, 5S)-4-azido-5-(hydroxymethyl) 
tetrahydrofuran-2-yl]-5-methylpyrimidine-
2, 4(1H, 3H)-Dione;
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Description : A  white  or  brownish  powder.  
A dideoxynucleoside compound in which 
the  3'-hydroxy  group  on  the  sugar 
moiety has been replaced by an azido 
group.  This  modification  prevents  the 
formation  of  phosphodiester  linkages 
which are needed for the completion of 
nucleic acid chains. The compound is a 
potent inhibitor of HIV replication, acting 
as a chain-terminator of viral DNA during 
reverse transcription. 
Solubility : Soluble in ethanol (750 g/l) TS (ethanol 
95%) , sparingly soluble in water.
Category : Anti-HIV  Agent,  Antimetabolite, 
Nucleoside  and  Nucleotide  Reverse 
Transcriptase Inhibitors.(Tripathi., 2008).
Storage :  Zidovudine  should  be  kept  in  a  tightly 
closed container, protected from light.
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PHARMACODYNAMICS
Mechanism of action
Zidovudine is  a  nucleoside  reverse  transcriptase inhibitor  (NRTI) 
with  activity  against  Human  Immunodeficiency  Virus  Type  1  (HIV-1). 
Zidovudine  is  phosphorylated  to  active  metabolites  that  compete  for 
incorporation  into  viral  DNA.  They inhibit  the HIV reverse  transcriptase 
enzyme competitively and act as a chain terminator of DNA synthesis. The 
lack of a 3'-OH group in the incorporated nucleoside analogue prevents 
the formation of the 5' to 3' phosphodiester linkage essential for DNA chain 
elongation, and therefore, the viral DNA growth is terminated.
Absorption
Rapid and nearly complete absorption from the gastrointestinal tract 
following oral administration; however, because of first-pass metabolism, 
systemic  bioavailability  of  zidovudine  capsules  and  solution  is 
approximately 65% (range, 52 to 75%). Bioavailability in neonates up to  
14 days of age is approximately 89%, and it decreases to approximately 
61% and 65% in neonates over 14 days of age and children 3 months to 
12 years, respectively. Administration with a high-fat meal may decrease 
the rate and extent of absorption.(Tripathi., 2008).
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Half life 
0.5-3 hours.
Distribution
The  apparent  volume  of  distribution  of  zidovudine,  following  
oral administration, is 1.6 ± 0.6 L/kg; and binding to plasma protein is low, 
< 38%.
Biotransformation
Hepatic metabolized by glucuronide conjugation to major, inactive 
metabolite,  3′-azido-3′-deoxy-5′-  O-beta-D-glucopyranuronosylthymidine 
(GZDV).
Elimination
Zidovudine is eliminated from the body primarily by renal excretion 
following metabolism in the liver (glucuronidation). In patients with severely 
impaired  renal  function  (CrCl<15  mL/min),  dosage  reduction  is 
recommended. Although the data are limited, zidovudine concentrations 
appear to be increased in patients with severely impaired hepatic function 
which may increase the risk of hematologic toxicity.
Drug interaction
Concomitant use of zidovudine with stavudine should be avoided 
since an antagonistic relationship has been demonstrated.
Some  nucleoside  analogues  affecting  DNA  replication,  such  as 
ribavirin,  antagonize  the  antiviral  activity  of  zidovudine  against  HIV-1; 
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concomitant use of such drugs should be avoided.
Concomitant use of zidovudine with doxorubicin should be avoided 
since an antagonistic relationship has been demonstrated.
Precautions
Zidovudine is eliminated from the body primarily by renal excretion 
following metabolism in the liver (glucuronidation).
Patients should be informed that the major toxicities of zidovudine 
are neutropenia and/or anemia.
Patients  should  be  informed  that  other  adverse  effects  of 
zidovudine include nausea and vomiting.
Adverse effects
 Asthenia  Headache
 Malaise  Anorexia
 Constipation  Nausea
 Vomiting
POLYMER PROFILE
ETHYL CELLULOSE
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Synonyms
Aquacoat ECD, Aqualon E 462, ethocel, surelease.
Chemical name
Cellulose ethyl ether
Description
Ethocel is tasteless, free flowing, white to light tan-coloured powder. 
Density
0.4 g/cm3.
Glass transition temperature
129 -133º C.
Solubility
Ethyl cellulose is practically insoluble in glycerin, propylene glycol, 
water.
Ethyl cellulose that contains   less than 46.5% of ethoxy group is 
freely  soluble  in  chloroform,  Methyl  acetate,  tetrahydrofuran,  aromatic 
hydrocarbons and ethanol.
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It  is  also  freely  soluble  in  ethanol,  ethyl  acetate,  methanol  and 
toluene.(Handbook of pharmaceutical exicipients, 2003).
Specific gravity
1.12-1.15 g/cm3.
Viscosity
5-100 m Pascal (7-100 cp).
Functional category:
Coating agent, flavoring fixative, tablet binder, tablet filler, viscosity 
increasing agent.
Method of manufacture
Ethyl  cellulose is prepared by treating purified cellulose (sourced 
from  chemical-grade  cotton,  linters  and  wood  pulp)  with  an  alkaline 
solution, followed by ethylation of the alkali. 
The manner ethyl group is added to cellulose can be described by 
the degree of substitution (DS). The DS designates the average number of 
hydroxyl positions on the anhydroglucose unit that have been reacted with 
ethyl chloride. Since each anhydroglucose unit of the cellulose molecule 
has three hydroxyl groups, the maximum DS is three.
54
Stability and storage conditions
Ethylcellulose is stable and slightly hygroscopic material. chemically 
resistant to alkali  and more sensitive to acid materials. Ethylcellulose is 
subjected  to  oxidative  degradation  in  the  sunlight  or  UV  radiation  at 
elevated temperature. This can be prevented by using an antioxidant and 
chemical additives that absorb light in 230-340 nm range.
It should be stored at a temperature not exceeding 32oC and in the 
areas  away  from  all  sources  of  heat.  It  should  not  be  stored  next  to 
peroxides or other oxidizing agents.
Safety
Ethylcellulose is widely used in oral and in topical pharmaceutical 
formulations.  It  is  also  used  in  food  products.  Ethylcellulose  is  not 
metabolized following oral consumption and therefore it is a non calorific 
substance. Because ethylcellulose it  is not recommended for parenteral 
formulations; parenteral usage may be harmful to the kidneys.
Ethyl  cellulose  is  generally  regarded  as  a  nontoxic  non 
allergenic and nonirritating material. Ethylcellulose intake is not considered 
as  a  health  hazard  and  WHO has  not  specified  and  acceptable  daily 
intake.
Incompatibilities
It is incompatible with microcrystalline wax and paraffin wax.
55
Applications in pharmaceutical formulations:
 To mask the unpleasant taste of drug.
 Hydrophobic coating agent for tablets and granules.
 Modified release of the drug.
 To improve the stability of the formulation.
 Used in cosmetics and food products.
 Thickness agent in creams, lotions and gels.
 Binders in tablets.
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EXPERIMENTAL WORK
MATERIALS USED
Zidovudine
• Gift sample from Ranbaxy laboratories.
Ethyl cellulose
•  Lobachemie
Acetonitrile
• Qualigens
Dichloromethane
• Lobachemie
Light liquid paraffin
• Lobachemie
Span 20
• Lobachemie
n-Hexane
• Lobachemie
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INSTRUMENTS AND EQUIPMENTS USED
UV spectrophotometer
• SHIMADZU UV 1650 PC
Electronic balance
• AND HR-200
Dissolution test apparatus
• LAB INDIA, DISSO 2000
FT-IR
• SHIMADZU FTIR-8400 S
Mechanical stirrer
• REMI MOTORS
IR - Hydraulic pellet press
• M - 15 KBr Press
pH Meter
• LI-120, Elico
Scanning electron microscope
• Jeol JSM - 6400
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METHODS
Preparation  of  ethyl  cellulose  microspheres  by  double  emulsion 
solvent diffusion technique.
Method Employed
All  microspheres  were  prepared  by  the  w/o/o  double  emulsion 
solvent diffusion method .The effect of various formulation and processing 
factors  on  microspheres  characteristics  were  investigated  by  changing 
polymer-drug ratio and the volume of external oil phase. Weighed amounts 
of ethylcellulose and zidovudine (AZT) (Different Ethylcellulose: AZT ratios 
were 1:0.25, 1:0.5, 1:0.75 and 1:1) were dissolved in 5 mL of a mixture of 
acetonitrile  and  dichloromethane  (1:1).  The  initial  w/o  emulsion  was 
formed by adding 2 mL of deionized water to the drug-polymer solution 
with constant stirring at 500 rpm for 5 min. The w/o primary emulsion was 
then  slowly  added  to  light  liquid  paraffin  (variable  volume  of  50  mL,  
100 mL) containing Span 20 (concentration of 2%  w/v)  as  a  surfactant 
with  constant stirring (speed 1000) for 2 h. The n-hexane (10 mL) was 
added to  harden the  formed microspheres and the  stirring  was  further 
continued  for  1  h.  The  resulting  microspheres  were  separated  by 
decantation, freed from liquid paraffin by repeated washing with n-hexane 
(3 × 50 mL) and finally air dried over a period of 12 h.
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Table: 3 Formulation of zidovudine microspheres using 
Ethylcellulose 
S.N
O Formulation 
zidovudin
e     (mg)
 Ethyl 
Cellulose
(mg)
Drug:poly
mer
Ratio
Light 
liquid 
paraffin 
(ml)
1 F1 250 mg 1000 mg 0.25:1 50
2 F2 500 mg 1000 mg 0.5:1 50
3 F3 750 mg 1000 mg 0.75:1 50
4 F4 1000 mg 1000 mg 1:1 50
5 F5 250 mg 1000 mg 0.25:1 100
6 F6 500 mg 1000 mg 0.5:1 100
7 F7 750 mg 1000 mg 0.75:1 100
8 F8 1000 mg 1000 mg 1:1 100
• Medium A- 50 ml light liquid paraffin.
• Medium B- 100 ml light liquid paraffin.
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PREFORMULATION STUDIES
Standard graph of zidovudine
• Preparation of stock solution:
• 100 mg of zidovudine dissolved in 100 ml of PH 7.4 phosphate  
buffer to get a concentration of 100 µg/ml.
• From this take 2 ml and made up to 100 ml with PH 7.4 phosphate 
buffer to get a concentration of solution 20 µg/ml.
Preparation of various concentrations of zidovudine solution
• 1ml of the stock solution was taken was made up to 10 ml with pH 
7.4 phosphate buffer to give 2µg/ml.
• 2ml of the stock solution was taken was made up to 10 ml with pH 
7.4 phosphate buffer to give 4µg/ml.
• 3ml of the stock solution was taken was made up to 10 ml with pH 
7.4 phosphate buffer to give 6µg/ml.
• 4ml of the stock solution was taken was made up to 10 ml with pH 
7.4 phosphate buffer to give 8µg/ml.
• 5ml of the stock solution was taken was made up to 10 ml with pH 
7.4 phosphate buffer to give 10µg/ml.
• 6ml of the stock solution was taken was made up to 10 ml with pH 
7.4 phosphate buffer to give 12µg/ml.
• 7ml of the stock solution was taken was made up to 10 ml with pH 
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7.4 phosphate buffer to give 14µg/ml.
• 8ml of the stock solution was taken was made up to 10 ml with pH 
7.4 phosphate buffer to give 16µg/ml.
• 9ml of the stock solution was taken was made up to 10 ml with pH 
7.4 phosphate buffer to give 18µg/ml.
• 10ml of the stock solution was taken which contains 2µg/ml.
Procedure
Various concentrations of zidovudine (2, 4, 6, 8, 10, 12, 14, 16, 18,  
20 µg/ml) were prepared as mentioned above. Absorbance of the solution 
was  measured  against  reagent  blank  at  266  nm  using  UV 
spectrophotometer.  A  standard  graph  between  concentration  Vs 
absorbance was plotted.  A straight  line passing through the origin  was 
obtained.
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Table 4 : Calibration data for the estimation of zidovudine
(2-20 µg/ml)
Concentration (µg/ml) Absorbance at 266 nm.
0 0.0000
2 0.1151
4 0.2180
6 0.3181
8 0.4132
10 0.5092
12 0.6391
14 0.7140
16 0.8030
18 0.9107
20 0.9920
63
Fig. 3 Stadard graph of Zidovudine  
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INTERACTION STUDY
Equipment
1. IR- hydraulic pellet press
2. Perkin Elmer FTIR.
Infrared (IR) absorption spectroscopy
To investigate any possible interactions between the drug and the 
polymers, the IR spectra of pure drug zidovudine and its physical mixtures 
(1:1)  with  Ethylcellulose  were  carried  out  using  shimadzu  IR-470 
spectrophotometer  (Tokyo,  Japan).The  samples  were  prepared  
as KBr disks compressed under a pressure of 6 ton/nm2. The wavelength 
selected  ranged  between  400-4000  cm-1 in  a  Perkin  Elmer  FTIR 
spectrophotometer.  The  IR  spectrum  of  the  physical  mixture  was 
compared with those of pure drug and polymers and matching was done 
to detect any appearance or disappearance of peaks.
Procedure
First a pinch of drug was added to the dried KBr, and triturated in 
mortar. The pellet was made by using pellet plate technique, and kept in 
IR chamber and scanned to get the spectra.  The same procedure was 
followed for the combination of drug-polymer too.
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By  comparing  the  IR  spectrum  of  drug  and  drug-polymer 
combinations, it was inferred that in both cases the characteristic peaks 
were obtained at same wave numbers. So from this it was concluded that 
no structural changes had occurred for the drug when combined with the 
polymers.
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Results and Discussion
The  compatibility  between  zidovudine  and  the  selected  polymer 
ethyl cellulose was evaluated using FTIR peak matching method. The IR 
spectra of pure drug, polymer and physical mixtures are shown in spectra 
above (fig.4, fig.5 and fig.6) respectively. There was no disappearance of 
peak  in  polymer  drug  mixture,  which  confirmed  the  absence  of  any 
chemical interaction between drug and polymer.
Drug content analysis
UV  spectrophotometric  method  was  employed  to  verify  the 
presence of drug in microspheres.30 mg of formulation was taken and the 
drug was extracted with  phosphate buffer  pH 7.4 and absorbance was 
measured  using  UV  spectrophotometer  at  266nm.  The  amount  of 
zidovudine in the microspheres was estimated with the help of standard 
graph. A study was performed on the percentage yield and percentage 
encapsulation efficiency.
Drug encapsulation efficiency  =
Amount of drug bound to the microspheres mg 
Total amount of applied drug mg 
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Table 5 : Amount of drug loaded in Ethylcellulose microspheres 
using 50 and 100 ml of dispersion medium.
Drug:Polymer
Amount of drug   loaded
50 ml of 
dispersion medium
100 ml of 
dispersion medium
0.25:1 6.31±0.5 5.74±0.5
0.5:1 11.85±0.3 11.61±0.7
0.75:1 13.25±0.5 13.06±0.6
1:1 16.66±0.5 15.69±0.2
Fig. 7 Amount of drug loaded in Ethylcellulose microspheres using 
50 and 100 ml of dispersion medium
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Results and Discussion
The amount of drug loaded in the microspheres prepared using 50 
and 100 ml of the light liquid paraffin was represented in fig.7. It was found 
that the amount of drug getting loaded into the microspheres increased 
when the amount of drug used for the preparation of the microspheres. 
The amount of drug getting loaded was found to be 6.31±0.5, 11.85±0.3, 
13.25±0.5 and 16.66±0.5 mg when the volume of dispersion medium was 
low i.e. 50ml and 5.74±0.5, 11.61±0.7, 13.06±0.6 and 15.69±0.2 mg when 
the volume of dispersion medium was high i.e. 100ml.
From the above results it was found that the amount of drug getting 
loaded into the microspheres was high when the volume of medium was 
low and less when the volume of medium was high.
The polymer ratio was found to be inversely proportional to drug 
loading capacity.
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Percentage Encapsulation efficiency of ethylcellulose microspheres
The  amount  of  zidovudine  present  in  the  microspheres  was 
determined  by  extracting  into  phosphate  buffer  (pH  7.4).  40  mg  of 
microspheres were crushed and powdered by using a mortar and pestle 
and  30mg  of  accurately  weighed  powder  was  extracted  into  100ml  of 
phosphate buffer (pH 7.4) by stirring at 1000 rpm for 2 h. The solution was 
filtered,  diluted  100  times  and  estimated  for  zidovudine  content  using 
UV/Visible spectrophotometer at 266 nm. (Das et al., 2005).
Percentage entrapped
(%) =
Amount of drug bound to the microspheres mg 
Total amount of applied drug mg 
×100
Table 6: Percentage encapsulation efficiency of ethyl cellulose
microspheres using 50 and 100 ml of dispersion medium
Drug:Polymer
Percentage of drug 
loaded
 50 ml of 
dispersion medium
100 ml of 
dispersion medium
0.25:1 51.22±0.5 48.12±0.6
0.5:1 54.29±0.6 52.18±0.2
0.75:1 58.26±0.3 57.27±0.5
1:1 65.12±0.5 62.57±0.4
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Fig. 8 Percentage encapsulation efficiency of ethyl cellulose
 microspheres using 50 and 100 ml of dispersion medium
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Results and Discussion
The percentage of drug loaded in the microspheres prepared using 
50 and 100 ml of the light liquid paraffin was represented in fig.8. It was 
found that the percentage of drug getting loaded into the microspheres 
was  directly  proportional  to  the  amount  of  drug.  The  amount  of  drug 
getting  loaded  was  found  to  be  51.22±0.5,  54.29±0.6,  58.26±0.3  and 
65.12±0.8 % when the volume of dispersion medium was low i.e. 50ml and 
48.12±0.6,  52.18±0.2,  57.27±0.5 and 62.57±0.4 % when the volume of 
dispersion medium was high i.e. 100ml.
From the above results it  was found that the percentage of drug 
getting  loaded  into  the  microspheres  was  high  when  the  volume  of 
medium was low and less when the volume of medium was high.
Percentage yield of ethylcellulose microspheres
The  percentage  yield  of  the  microspheres  was  calculated  by 
accurately weighing out the amount of product obtained at the end of each 
batch of each batch of formulation. The formula given below was used to 
calculate  the  % yield  of  the  microspheres.  (Sunit  Kumar  Sahoo et  al., 
2005).
Percentage yield (%) =
Amount of recored microparticle mg 
The theoratical content mg 
×100
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Table 7: Percentage yield of ethylcellulose microspheres using
 50 and 100 ml of dispersion medium
Drug:Polymer
Percentage yield
50 ml of 
dispersion 
medium
100 ml of 
dispersion 
medium
0.25:1 49.04 50.24
0.5:1 45.08 44.9
75:1 57.0 56.9
1:1 61.8 59.8
Fig. 9 Percentage yield of Ethylcellulose Microspheres using 50 and 
100 ml of dispersion medium.
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Results and Discussion
The  percentage  yield  of  microspheres  by  using  various  drug 
polymer ratio and different volume of dispersion medium was shown in fig 
9. The percentage yield in 50 ml of dispersion medium was found to be 
49.04%, 45.08%, 57.0% and 61.8%. The percentage yield in 100 ml of 
distribution medium was found to be 50.24%, 44.9%, 56.9% and 59.8%.
From the above results it was found that the percentage yield was 
high when the volume of dispersion medium used was 50 ml.
DETERMINATION OF SIZE AND SHAPE OF MICROSPHERES
Determination  of  size  and  shape  of  microspheres  using  scanning 
electron microscope:-
The  surface  morphology  and  internal  texture  of  zidovudine 
microspheres were observed by a scanning electron microscope (SEM). 
SEM  photographs  were  taken  on  3kv  magnification  at  18oC.  Before 
scanning the particles were sputtered with platinum to make the surface 
conductive. The photograph shows that the particles are spherical enough 
and have a smooth surface.
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Fig. 10, 11 Scanning electron microscope pictures of ethyl cellulose 
microspheres
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Measurement  of  particle  size  determination  of  microspheres  by 
optical microscopy method:-
Microscope was cleaned and focused for bright light eyepiece was 
fixed in microscope with micrometer. Eyepiece micrometer was calibrated 
using standard stage micrometer. Few drops of sample were mounted in a 
glass slide. Particle size was measured using standard stage micrometer. 
100 particles were tabulated for predicting the average mean diameter and 
particle size distribution.
Arithmetic mean = Σnd/Σn
Table: 8 calibration of eyepiece micrometer
Stage 
Micrometer 0 13.4 18.8 26.8 47
Eyepiece 
Micrometer 0 10 14 20 35
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Table: 9 Particle size determination by optical microscopic method
 for formulations prepared using 50 ml dispersion medium
Formulation 
code
Particle size 
range (µm)
Mean 
diameter
(µm) (d)
Number of 
particles (n) nxd
F1
0-100 50 8 400
100-200 150 5 750
200-300 250 4 1000
300-400 350 54 18900
400-500 450 21 9450
500-600 550 8 4400
F2
0-100 50 4 200
100-200 150 7 1050
200-300 250 21 5250
300-400 350 48 16800
400-500 450 13 5850
500-600 550 7 3850
F3
0-100 50 4 200
100-200 150 4 600
200-300 250 18 4000
300-400 350 52 18200
400-500 450 17 7650
500-600 550 5 2750
F4
0-100 50 5 250
100-200 150 7 1050
200-300 250 15 3750
300-400 350 47 16450
400-500 450 20 9000
500-600 550 6 3300
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Fig.12 Particle size determination by optical microscope method 
using
 for formulations prepared using 50 ml dispersion medium 
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Results and Discussion
The number of particles present in each size range was shown in 
fig 12 for the formulations made using 50 ml of light liquid paraffin and 
drug polymer ratio of (0.25:1, 0.5:1, 0.75:1, 1:1). The highest number of 
particles were found in the range of 300-400 µm.
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Table: 10 Particle size determination by optical microscopic method
 for formulations prepared using 100 ml dispersion medium.
Fig. 13 Particle size determination by optical microscope method for 
formulations prepared using 100 ml dispersion medium 
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Results and discussion
The number of particles present in each size range was shown in 
fig 13 for the formulations made using 100 ml of light liquid paraffin and 
drug polymer ratio of 0.25:1, 0.5:1, 0.75:1 and 1:1. The highest number of  
particles was found in the range of 300-400 µm.
Arithmetic mean:
F1 = 349.00 µm F 5= 307.00 µm
F 2= 330.00 µm F 6= 352.00 µm
F 3= 334.00 µm F 7= 351.00 µm
F 4= 338.00 µm F 8= 337.00 µm
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4.5  In Vitro Drug Release Studies
The USP basket-type dissolution (Type II) test apparatus was used 
for  in vitro release studies. A weighed quantity of the microspheres was 
suspended  in  900  ml  of  phosphate  buffer  (pH  7.4).  The  dissolution 
medium was stirred at 100 rpm and maintained at constant temperature 
(37±1 0 C). At preset time intervals 5 ml aliquots were withdrawn at 0, 1, 2, 
4,  6,  12,  and  24  hours  and  replaced  by  an  equal  volume  of  fresh 
dissolution medium to maintain sink condition. After suitable dilution, the 
samples were analyzed at 266 nm using UV-Visible spectrophotometer.
Calculation
To calculate the actual percentage release of drug it is necessary to 
calculate the theoretical release of the drug. It can be calculated by using 
the general formula,
Theoretical  release  =  (total  amount  o  drug  loaded  in  1mg  of 
microspheres) x (amount of microspheres taken for in vitro studies)
The  exact  percentage  release  of  drug  can  be  obtained  by  the 
general formula:
Exact percentage release or 
Cumulative release = Actual Re leaseTheoretical Re lease
X 100           
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IN VITRO DRUG RELEASE STUDIES
Table: 11 Percentage of drug released for formulations prepared
 using 50 ml of dispersion medium.
S.No Time(hrs)
Cumulative percentage release 
F1 F2 F3 F4
1 0 0.98±0.02 0.82±0.08 0.53±0.05 0.73±0.04
2 1 12.74±0.04 15.7±0.05 21.06±0.07 20.78±0.05
3 2 20.09±0.06 20.66±0.07 24.0±0.05 24.2±0.08
4 4 23.52±0.05 24.51±0.04 29.33±0.04 30.56±0.05
5 6 25.98±0.07 26.17±0.05 34.66±0.08 33.74±0.04
6 12 36.76±0.07 44.07±0.07 48.0±0.04 45.72±0.07
7 24 57.85±0.08 60.06±0.04 61.3±0.05 64.05±0.08
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Chapter V                                               Experimental Work
Fig. 14 Percentage release of zidovudine microspheres prepared using 50 ml of dispersion medium 
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86
Results and Discussion:
The in vitro release profile was shown in fig.14. All the formulation 
was found to show sustained release. The release profile of F1, F2, F3 & 
F4 was found to be 57.85%, 60.06%, 61.3% & 64.05% respectively at the 
end  of  24  hours.  The  results  suggest  that  the  polymer  concentration 
having a significant influence on the release profile. It  was found to be 
inversely proportional. As the drug polymer ratio increase there was a low 
release profile. 1:1 drug polymer ratio can be further evaluated in vivo to 
optimize the formulation.
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Table : 12  Percentage of drug released for formulations prepared 
using 100 ml of dispersion medium.
S.No Time (hrs)
Cumulative percentage release
F5 F6 F7 F8
1 0 1.1±0.03 0.8±0.06 0.78±0.05 0.71±0.03
2 1 14.07±  0.04 16.17± 0.18
19.56± 0.0
6
20.57± 0.0
8
3 2 22.11±0.08 24.52±0.08 24.93±0.06 24.4±0.05
4 4 28.14±0.06 26.51±0.03 30.7±0.05 30.62±0.06
5 6 31.25±0.05 27.49±0.06 35.43±0.08 32.73±0.03
6 12 39.19±0.07 47.97±0.03 48.81±0.05 46.41±0.08
7 24 61.3±0.08 61.45±0.05 62.99±0.07 66.94±0.03
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Fig. 15 Percentage release of zidovudine microspheres prepared using 100 ml of dispersion medium
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Results and Discussion
The in vitro release profile was shown in Fig.15. All the formulation 
was found to show sustained release. The release profile of F5, F6, F7 & 
F8 was found to be 61.3%, 61.45%, 62.99% & 66.94% respectively at the 
end  of  24  hours.  The  results  suggest  that  the  polymer  concentration 
having a significant influence on the release profile. It  was found to be 
inversely proportional. As the drug polymer ratio increase there was a low 
release profile. 1:1 drug polymer ratio can be further evaluated in vivo to 
optimize the formulation.
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SUMMARY AND CONCLUSION
SUMMARY
Novel  drug  delivery  system  is  finding  more  attention  in 
pharmaceutical  industries  due  to  its  various  advantages.  In  the  line 
sustained/controlled release formulations are more focused for improving 
the drug bioavailability with less dosing frequency. Zidovudine is one such 
compound having a poor bioavailability with high dosing frequency. The 
present investigation is focused to develop a suitable sustained release 
formulation  for  achieving  better  bioavailability  and  reduce  dosing 
frequency.
Compatibility Studies
Zidovudine was formulated as microspheres using ethylcellulose. 
Compatibility studies were carried out using FTIR. The results suggest no 
evidence  of  any  interaction.   Different  batches  containing  various 
concentrations of drug, polymer with varying volume of dispersion medium 
was prepared by double emulsion solvent diffusion technique.
In Vitro release studies
The in vitro release suggest that low volume of dispersion medium 
and low polymer ratio (F4) showed 64.05% of release at the end of 24 hrs 
with 65.12 % entrapment.
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CONCLUSION
It  is  evident  that  zidovudine  loaded  ethylcellulose  microspheres 
showed  better  sustained  release  profile  which  is  up  to  24  hrs.  The 
prepared  formulation  can  be  further  evaluated  to  achieve  a  better 
bioavailability.  IN  VIVO  studies  can  be  carried  out  to  optimize  the 
Zidovudine  microspheres  using  ethyl  cellulose.  The  pharmacokinetic 
behavior of the formulated microspheres can be studies for optimization of 
the formulation. 
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